Elanco Animal Health (ELAN) to Release Quarterly Earnings on Wednesday

Elanco Animal Health (NYSE:ELAN) will be issuing its quarterly earnings data before the market opens on Wednesday, May 8th. Analysts expect the company to announce earnings of $0.26 per share for the quarter. Elanco Animal Health has set its Q1 guidance at $0.25-0.28 EPS and its FY24 guidance at $0.87-0.95 EPS.Parties that are interested in registering for the company’s conference call can do so using this link.

Elanco Animal Health (NYSE:ELAN) last announced its quarterly earnings results on Monday, February 26th. The company reported $0.08 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.02). The firm had revenue of $1.04 billion during the quarter, compared to the consensus estimate of $1 billion. Elanco Animal Health had a positive return on equity of 6.44% and a negative net margin of 27.87%. The business’s revenue for the quarter was up 5.1% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.19 EPS. On average, analysts expect Elanco Animal Health to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Elanco Animal Health Stock Performance

Shares of Elanco Animal Health stock opened at $13.53 on Monday. The company has a debt-to-equity ratio of 0.92, a current ratio of 2.75 and a quick ratio of 1.35. The stock has a market cap of $6.69 billion, a price-to-earnings ratio of -5.41, a PEG ratio of 1.42 and a beta of 1.34. The firm’s 50-day moving average is $15.08 and its 200 day moving average is $13.96. Elanco Animal Health has a 1 year low of $7.88 and a 1 year high of $16.88.

Insider Buying and Selling at Elanco Animal Health

In related news, Director R David Hoover acquired 20,000 shares of the business’s stock in a transaction on Wednesday, March 6th. The stock was acquired at an average cost of $16.14 per share, with a total value of $322,800.00. Following the acquisition, the director now directly owns 185,000 shares in the company, valued at approximately $2,985,900. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 0.57% of the company’s stock.

Wall Street Analyst Weigh In

ELAN has been the topic of several research analyst reports. Morgan Stanley upped their target price on shares of Elanco Animal Health from $16.00 to $17.00 and gave the company an “overweight” rating in a research note on Tuesday, February 27th. TheStreet upgraded shares of Elanco Animal Health from a “d+” rating to a “c-” rating in a research note on Friday, February 23rd. Barclays upped their target price on shares of Elanco Animal Health from $18.00 to $19.00 and gave the company an “overweight” rating in a research note on Tuesday, February 27th. Finally, The Goldman Sachs Group upped their target price on shares of Elanco Animal Health from $12.50 to $14.00 and gave the company a “sell” rating in a research note on Tuesday, February 27th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $16.71.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.